Navigation Links
Kuvan Receives Marketing Approval in the European Union
Date:12/9/2008

h is currently in Phase 2 clinical development for the treatment of peripheral arterial disease and sickle cell disease, and PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase 1 clinical development for the treatment of PKU. For additional information, please visit http://www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

Forward-Looking Statement

This press release contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including, without limitation, statements about: the continued development and commercialization of Kuvan and BioMarin's other products and product candidates and actions by regulatory authorities. These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others: our success in the continued commercialization of Kuvan; the content and timing of decisions by the U.S. Food and Drug Administration, the European Commission and other regulatory authorities concerning each of the described products and product candidates; and those factors detailed in BioMarin's filings with the Securities and Exchange Commission, including, without limitation, the factors contained under the caption "Risk Factors" in BioMarin's 2007 Annual Report on Form 10-K, as amended, and the factors contained in BioMarin's reports on Form 10-Q and Form 8-K. Stockholders are urged not to place undue reliance on forward-looking statements, which speak only as of the date hereof. BioMarin is under no obligation, and expressly disclaims any obligation to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise.

BioMarin(R), Naglazyme(R) and Kuvan(R
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Kuvan Receives Positive Opinion From CHMP for European Approval
2. Kuvan, Naglazyme and Aldurazyme Data to Be Presented at the 57th Annual Meeting of the American Society of Human Genetics
3. Exclusive Rights to Kuvan(TM) Data Licensed to Asubio Pharma in Japan
4. Align Technology Receives Expanded Regulatory Approval in Japan
5. Adecco Receives Honor From Alcon Laboratories
6. ANA598 Receives Fast Track Designation From the FDA for the Treatment of Chronic Hepatitis C Infection
7. EastMed Inc. receives FDA clearance to market uresta(TM) in the U.S.
8. SuperGen Receives Clearance to Begin Clinical Trials With SGI-1776, a PIM Inhibitor
9. Serica Technologies Receives ISO Certification, Meets International Standards for Medical Device Manufacturing
10. Bavarian Nordic Receives USD 25 Million Milestone Payment After Submission of Important IMVAMUNE(R) Data to The U.S. Health Authorities
11. Cellectricon Receives Milestone Order for Cellaxess(R)HT, the Worlds First High Throughput RNAi Screening System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... PARIS , July 30, 2015 ... leader, reports results for the second quarter of ... the group,s results and its performance in different ... transcript:  http://www.eurobusinessmedia.com/ceo-direct/sanofi/sanofi-h1-2015-results-interview-with-ceo-olivier-brandicourt?utm_source=ceo-direct&utm_medium=wire ... - Q2 results - Performance drivers ...
(Date:7/29/2015)... Japan (Q2 2015: +14% CER / 20% of sales) ... in China , as well as solid contributions from Korea, ... Europe / Middle East / ... in Germany , Turkey and the ... 49% of sales) grew 11%, excluding U.S. HPV sales, on demand across all ...
(Date:7/29/2015)... (PRWEB) , ... July 29, 2015 , ... ... manufacturer and supplier, announces the launch of their 2nd generation cell therapy POD® ... current miniPOD CT, but it also represents a new POD® design. , ...
(Date:7/29/2015)... NEW YORK , July 29, 2015 /PRNewswire/ ... neuropathology testing, announces increased partnerships with VA and ... offers Epidermal Nerve Fiber Density (ENFD) and Sweat ... of small fiber neuropathy ( https://therapath.com/skin ). ... Epidermal Nerve Fiber Density (ENFD) on punch skin ...
Breaking Biology Technology:QIAGEN Reports Results for Second Quarter and First Half of 2015 2QIAGEN Reports Results for Second Quarter and First Half of 2015 3QIAGEN Reports Results for Second Quarter and First Half of 2015 4QIAGEN Reports Results for Second Quarter and First Half of 2015 5QIAGEN Reports Results for Second Quarter and First Half of 2015 6QIAGEN Reports Results for Second Quarter and First Half of 2015 7QIAGEN Reports Results for Second Quarter and First Half of 2015 8QIAGEN Reports Results for Second Quarter and First Half of 2015 9QIAGEN Reports Results for Second Quarter and First Half of 2015 10G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 2G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 3Neuropathology services for VA and Military health systems 2
... Corporation (OTC Bulletin Board: MFLU) announced today that the ... Monday, November 2, 2009, after the closing of the ... ) , Michael C. Ferrara, President and Chief ... Finance and Chief Accounting Officer, will host a conference ...
... -- In response to requests from clients, Schulman ... , The Schulman Canadian Board,s first official meeting is ... are conducted in both the U.S. and Canada, Canadian and ... to maintain consistency. , "Our clients have asked us to ...
... The Board of Directors of Biomoda, Inc. (OTC Bulletin ... cancer detection medical diagnostics company, has elected Maria Zannes ... the Biomoda Board May 1, 2008. , "Maria,s extraordinary ... perfect individual to safeguard our commitment to good corporate ...
Cached Biology Technology:Microfluidics International Corporation to Report Third Quarter 2009 Financial Results on November 2, 2009 2Microfluidics International Corporation to Report Third Quarter 2009 Financial Results on November 2, 2009 3Schulman Associates IRB Establishes an Institutional Review Board in Canada 2Biomoda Board of Directors Names New Corporate Secretary 2
(Date:7/13/2015)... Jul. 13, 2015 NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce ... patent 62/188684 for BEHAVIORAL-DIRECTED AUTHENTIATION METHOD ... convenient and secure method to make payments.  With ... methods, introduced with its groundbreaking voice-direct payment patent ...
(Date:7/8/2015)... , July 8, 2015 Summary Pancreatic ... the fourth most fatal, with a mortality rate of ... prognosis of pancreatic cancer patients has highlighted a significant ... is not being met by the current market. ... of products with varying molecule types and mechanisms of ...
(Date:7/7/2015)... MOUNTAIN VIEW, Calif. , July 7, 2015 ... mobile biometrics market, Frost & Sullivan recognizes Credence ... & Sullivan Entrepreneurial Company of the Year ... product suite to aid in its mission of ... and under-recognized populations globally. As Credence ID was ...
Breaking Biology News(10 mins):NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5
... scleroderma has slowed Tracy Zinn but it has not stopped ... accommodating employer, Zinn is now in her 13th year as ... But, many with the incapacitating disease are not as fortunate. ... people with systemic scleroderma, also known as systemic sclerosis, is ...
... 2011 DigitalPersona, Inc. , a global provider ... Pizza Hut™ franchisee Rage, Inc. has rolled out ... locations throughout the east coast in South Carolina, North ... By deploying fingerprint biometrics as a part of their ...
... 2001--Eating nuts every day could help control Type 2 ... from St. Michael,s Hospital and the University of Toronto. ... Diabetes Care , a team of researchers led ... Nutritional Sciences; St. Michael,s Hospital Risk Factor Modification Centre) ...
Cached Biology News:Scleroderma study identifies roadblocks to employment 2Scleroderma study identifies roadblocks to employment 3Pizza Hut Franchisee Saves Dough by Slicing Payroll Fraud and Leavening Store Revenue with Digital Persona Fingerprint Biometrics 2A 'nutty' solution to type 2 diabetes management 2
Kit contains: Bio-Rad Amplification Reagent, 2x Amplification Diluent, Streptavidin-HRP, Blocking Reagent, and Phosphate Buffered Saline....
These macrocarriers are for the biolistic PDS-1000 He and Hepta systems. Supplied as 500 macrocarriers....
Intestinal Epithelium Differentiation Environment...
Hepatocyte Differentiation Environment...
Biology Products: